<p>Tuzulby is a medicine used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years.</p><p>It is used as part of a comprehensive treatment strategy that typically involves psychological, educational and other interventions and is used when these measures alone do not control their symptoms well enough.</p><p>Tuzulby contains the active substance methylphenidate hydrochloride and is a ‘hybrid’ medicine. This means that it is similar to a ‘reference medicine’ containing the same active substance, but there are differences between the two. Tuzulby tablets release the active substance over a longer period of time than the reference medicine does. The reference medicine is Ritalin.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth Revision (ICD-10) and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptoms.</p></div>
Therapeutic Area (MeSH)
ATC Code
N06BA04
ATC Item
N/A
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| methylphenidate hydrochloride | N/A | methylphenidate hydrochloride |
EMA Name
Tuzulby
Medicine Name
Tuzulby
Aliases
N/ANo risk management plan link.
